Effect of intravenous vitamin C on chemotherapy adverse effects in nasopharyngeal cancer patients: A randomized double-blinded, placebo-controlled trial phase III.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

TCTR

Registry ID

TCTR20190316003

Enrollment

Registered

2019-03-16

Start date

2019-03-08

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nasopharyngeal cancer patients Adverse effect, chemotherapy, nasopharyngeal cancer, intravenous vitamin C, side effect

Interventions

2 g of Intravenous Vitamin C (4mL) mix in 50mL 5%DW IV drip in 1 hr before chemotherapy,50mL 5%DW IV drip in 1 hr before chemotherapy

Active Comparator Drug,Placebo Comparator Drug

Intravenous Vitamin C 2g,Placebo

Eligibility

Sex/Gender

All

Age

15 Years to 90 Years

Inclusion criteria

Inclusion criteria: Nasopharyngeal cancer patients who plan to treat with Concurrent Chemoradiation

Exclusion criteria

Exclusion criteria: - Glucose-6-phosphate Dehydrogenase (G-6-PD deficiency) patient - Renal stone patient

Design outcomes

Primary

Measure	Time frame
Reduction of chemotherapy adverse effect 2 wk after chemotherapy Common Terminology Criteria for Adverse Events version 5.0,Reduction of chemotherapy induced electrolytes imbalance at Nadir of each cycle Common Terminology Criteria for Adverse Events version 5.0	—

Secondary

Measure	Time frame
Reduction of chemotherapy induced hematological parameters at Nadir of each cycle Common Terminology Criteria for Adverse Events version 5.0	—

Countries

Thailand

Contacts

Public ContactManupol Tangthongkum

Faculty of Medicine, Prince of Songkla University

tmanupol@gmail.com0873913877

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026